| Oct 8 |
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
|
| Oct 4 |
OncoCyte Secures Funding Through Private Share Sale
|
| Aug 12 |
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
|
| Aug 7 |
OncoCyte Q2 2024 Earnings Preview
|
| Aug 1 |
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
|
| Jul 11 |
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode
|
| Jun 24 |
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
|
| Jun 17 |
OncoCyte appoints CFO
|
| Jun 17 |
Oncocyte Appoints Andrea James as Chief Financial Officer
|
| Jun 5 |
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
|
